Product Images Imatinib Mesylate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Imatinib Mesylate NDC 51407-269 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

51407-269-90LB IMATINIB MESYLATE 100 MG TAB.jpg - 51407 269 90LB IMATINIB MESYLATE 100 MG TAB

51407-269-90LB IMATINIB MESYLATE 100 MG TAB.jpg - 51407 269 90LB  IMATINIB MESYLATE 100 MG TAB

The text describes a medication with the NDC code 51407-269-90, called Imatinib Mesylate. The medication is in the form of tablets and is available in a pack of 90. The dosage information can be found in the package insert. The medication must be stored at a temperature range of 20° to 25°C (68° to 77°F) and protected from moisture. It should be kept out of reach of children and closed with a child-resistant closure. The medication is manufactured by Mylan LLC, Caguas PR, 00726, and packaged by GSMS, Incorporated, Camarilio, CA 83012 USA.*

51407-270-30LB IMATINIB MESYLATE 100 MG TAB.jpg - 51407 270 30LB IMATINIB MESYLATE 100 MG TAB

51407-270-30LB IMATINIB MESYLATE 100 MG TAB.jpg - 51407 270 30LB  IMATINIB MESYLATE 100 MG TAB

NDC 51407-270-30 is a pack of Imatinib Mesylate Tablets containing 400mg of imatinib per each film-coated tablet manufactured by Mylsn LLC in Caguas PR, 00725 and Packaged by GSMS, Incorporated in Camarilio, CA 83012 USA. The tablets should be stored in a tight, light-resistant container at a temperature between 20 to 26°C and protected from moisture. The pack includes further details about the dosage and usage.*

Imatinib structural formula - image 01

Imatinib structural formula - image 01

Figure 1: Progression Free Survival (ITT Principle) - image 04

Figure 1: Progression Free Survival (ITT Principle) - image 04

This text appears to describe a study involving patients, with some data presented in a table format. Unfortunately, the text is incomplete and some characters are missing, making it difficult to fully understand the purpose and results of the study. However, it does appear to include information about patients with "progression" and "censorship" or discontinuation, as well as hazard ratios and a statistical test. Without more complete information, it is not possible to provide a useful description beyond this.*

Figure 2: Time to Progression to AP or BC (ITT Principle) - image 05

Figure 2: Time to Progression to AP or BC (ITT Principle) - image 05

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.